{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:46:16Z","timestamp":1785804376947,"version":"3.56.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T00:00:00Z","timestamp":1350345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1038\/nrneph.2012.217","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T09:11:14Z","timestamp":1350378674000},"page":"691-699","source":"Crossref","is-referenced-by-count":40,"title":["Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy"],"prefix":"10.1038","volume":"8","author":[{"given":"Sara S.","family":"Roscioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J. L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.","family":"Lambers Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,16]]},"reference":[{"key":"BFnrneph2012217_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","volume":"48","author":"M MacKinnon","year":"2006","unstructured":"MacKinnon, M.  et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am. J. Kidney Dis. 48, 8\u201320 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012217_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s00392-008-0668-3","volume":"97","author":"C Werner","year":"2008","unstructured":"Werner, C.  et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin. Res. Cardiol. 97, 418\u2013431 (2008).","journal-title":"Clin. Res. Cardiol."},{"key":"BFnrneph2012217_CR3","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw, D.  et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 65, 2309\u20132320 (2004).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","volume":"110","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw, D.  et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921\u2013927 (2004).","journal-title":"Circulation"},{"key":"BFnrneph2012217_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/eurheartj\/ehr017","volume":"32","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp, F. A.  et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur. Heart J. 32, 1493\u20131499 (2011).","journal-title":"Eur. Heart J."},{"key":"BFnrneph2012217_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.HYP.0000252676.46043.18","volume":"49","author":"KL Ong","year":"2007","unstructured":"Ong, K. L., Cheung, B. M., Man, Y. B., Lau, C. P. & Lam, K. S. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999\u20132004. Hypertension 49, 69\u201375 (2007).","journal-title":"Hypertension"},{"key":"BFnrneph2012217_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","volume":"41","author":"J Coresh","year":"2003","unstructured":"Coresh, J., Astor, B. C., Greene, T., Eknoyan, G. & Levey, A. S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 41, 1\u201312 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012217_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback, A. S. & Klemmer, P. J. The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 3, 486\u2013492 (2007).","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"BFnrneph2012217_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","volume":"17","author":"KC Gilbert","year":"2010","unstructured":"Gilbert, K. C. & Brown, N. J. Aldosterone and inflammation. Curr. Opin. Endocrinol. Diabetes Obes. 17, 199\u2013204 (2010).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"BFnrneph2012217_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0272-6386(01)80115-3","volume":"37","author":"M Epstein","year":"2001","unstructured":"Epstein, M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am. J. Kidney Dis. 37, 677\u2013688 (2001).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012217_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.2174\/157016111796642689","volume":"9","author":"F Waanders","year":"2011","unstructured":"Waanders, F.  et al. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. Curr. Vasc. Pharmacol. 9, 594\u2013605 (2011).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"BFnrneph2012217_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","volume":"46","author":"S Bianchi","year":"2005","unstructured":"Bianchi, S., Bigazzi, R. & Campese, V. M. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am. J. Kidney Dis. 46, 45\u201351 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012217_CR13","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi, S., Bigazzi, R. & Campese, V. M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 70, 2116\u20132123 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR14","doi-asserted-by":"publisher","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","volume":"6","author":"L Boesby","year":"2011","unstructured":"Boesby, L., Elung-Jensen, T., Klausen, T. W., Strandgaard, S. & Kamper, A. L. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS ONE 6, e26904 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrneph2012217_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJM200109203451215","volume":"345","author":"A Chrysostomou","year":"2001","unstructured":"Chrysostomou, A. & Becker, G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N. Engl. J. Med. 345, 925\u2013926 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012217_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"A Chrysostomou","year":"2006","unstructured":"Chrysostomou, A., Pedagogos, E., MacGregor, L. & Becker, G. J. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin. J. Am. Soc. Nephrol. 1, 256\u2013262 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012217_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1291\/hypres.31.59","volume":"31","author":"Y Furumatsu","year":"2008","unstructured":"Furumatsu, Y.  et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens. Res. 31, 59\u201367 (2008).","journal-title":"Hypertens. Res."},{"key":"BFnrneph2012217_CR18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein, M.  et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 1, 940\u2013951 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012217_CR19","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.transproceed.2010.08.024","volume":"42","author":"ME Gonz\u00e1lez","year":"2010","unstructured":"Gonz\u00e1lez, M. E.  et al. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months. Transplant. Proc. 42, 2899\u20132901 (2010).","journal-title":"Transplant. Proc."},{"key":"BFnrneph2012217_CR20","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. & Toto, R. D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641\u20132650 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012217_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","volume":"21","author":"R Rachmani","year":"2004","unstructured":"Rachmani, R.  et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet. Med. 21, 471\u2013475 (2004).","journal-title":"Diabet. Med."},{"key":"BFnrneph2012217_CR22","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"K Rossing","year":"2005","unstructured":"Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F. & Parving, H. H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28, 2106\u20132112 (2005).","journal-title":"Diabetes Care"},{"key":"BFnrneph2012217_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A Sato","year":"2005","unstructured":"Sato, A., Hayashi, K. & Saruta, T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am. J. Hypertens. 18, 44\u201349 (2005).","journal-title":"Am. J. Hypertens."},{"key":"BFnrneph2012217_CR24","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"KJ Schjoedt","year":"2005","unstructured":"Schjoedt, K. J.  et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 68, 2829\u20132836 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt, K. J.  et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70, 536\u2013542 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR26","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3109\/08860220903216121","volume":"31","author":"E Sengul","year":"2009","unstructured":"Sengul, E., Sahin, T., Sevin, E. & Yilmaz, A. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease. Ren. Fail. 31, 928\u2013932 (2009).","journal-title":"Ren. Fail."},{"key":"BFnrneph2012217_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","volume":"52","author":"L Tylicki","year":"2008","unstructured":"Tylicki, L.  et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am. J. Kidney Dis. 52, 486\u2013493 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012217_CR28","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker, A. H.  et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J. Hypertens. 24, 2285\u20132292 (2006).","journal-title":"J. Hypertens."},{"key":"BFnrneph2012217_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato, A., Hayashi, K., Naruse, M. & Saruta, T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41, 64\u201368 (2003).","journal-title":"Hypertension"},{"key":"BFnrneph2012217_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s11906-011-0202-2","volume":"13","author":"MJ Volk","year":"2011","unstructured":"Volk, M. J., Bomback, A. S. & Klemmer, P. J. Mineralocorticoid receptor blockade in chronic kidney disease. Curr. Hypertens. Rep. 13, 282\u2013288 (2011).","journal-title":"Curr. Hypertens. Rep."},{"key":"BFnrneph2012217_CR31","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1210\/jc.2003-032149","volume":"89","author":"DG Levy","year":"2004","unstructured":"Levy, D. G., Rocha, R. & Funder, J. W. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J. Clin. Endocrinol. Metab. 89, 2736\u20132740 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2012217_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1053\/ajem.2000.7344","volume":"18","author":"A Mattu","year":"2000","unstructured":"Mattu, A., Brady, W. J. & Robinson, D. A. Electrocardiographic manifestations of hyperkalemia. Am. J. Emerg. Med. 18, 721\u2013729 (2000).","journal-title":"Am. J. Emerg. Med."},{"key":"BFnrneph2012217_CR33","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","volume":"50","author":"AS Desai","year":"2007","unstructured":"Desai, A. S.  et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J. Am. Coll. Cardiol. 50, 1959\u20131966 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrneph2012217_CR34","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"LM Einhorn","year":"2009","unstructured":"Einhorn, L. M.  et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med. 169, 1156\u20131162 (2009).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph2012217_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","volume":"46","author":"KB Shah","year":"2005","unstructured":"Shah, K. B., Rao, K., Sawyer, R. & Gottlieb, S. S. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J. Am. Coll. Cardiol. 46, 845\u2013849 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrneph2012217_CR36","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2169\/internalmedicine.46.6415","volume":"46","author":"K Takaichi","year":"2007","unstructured":"Takaichi, K., Takemoto, F., Ubara, Y. & Mori, Y. Analysis of factors causing hyperkalemia. Intern. Med. 46, 823\u2013829 (2007).","journal-title":"Intern. Med."},{"key":"BFnrneph2012217_CR37","doi-asserted-by":"publisher","first-page":"F593","DOI":"10.1152\/ajprenal.00454.2003","volume":"287","author":"P Meneton","year":"2004","unstructured":"Meneton, P., Loffing, J. & Warnock, D. G. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am. J. Physiol. Renal Physiol. 287, F593\u2013F601 (2004).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2012217_CR38","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/0026-0495(74)90032-8","volume":"23","author":"MS Oh","year":"1974","unstructured":"Oh, M. S.  et al. A mechanism for hyporeninemic hypoaldosteronism in chronic renal disease. Metabolism 23, 1157\u20131166 (1974).","journal-title":"Metabolism"},{"key":"BFnrneph2012217_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1056\/NEJM197209212871201","volume":"287","author":"M Schambelan","year":"1972","unstructured":"Schambelan, M., Stockigt, J. R. & Biglieri, E. G. Isolated hypoaldosteronism in adults. A renin-deficiency syndrome. N. Engl. J. Med. 287, 573\u2013578 (1972).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012217_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/ki.1980.14","volume":"17","author":"RA DeFronzo","year":"1980","unstructured":"DeFronzo, R. A. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int. 17, 118\u2013134 (1980).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR41","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","volume":"58","author":"GL Bakris","year":"2000","unstructured":"Bakris, G. L.  et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 58, 2084\u20132092 (2000).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/01.HYP.31.2.575","volume":"31","author":"S Csukas","year":"1998","unstructured":"Csukas, S., Hanke, C. J., Rewolinski, D. & Campbell, W. B. Prostaglandin E2-induced aldosterone release is mediated by an EP2 receptor. Hypertension 31, 575\u2013581 (1998).","journal-title":"Hypertension"},{"key":"BFnrneph2012217_CR43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/106002809002400305","volume":"24","author":"L Aull","year":"1990","unstructured":"Aull, L., Chao, H. & Coy, K. Heparin-induced hyperkalemia. DICP 24, 244\u2013246 (1990).","journal-title":"DICP"},{"key":"BFnrneph2012217_CR44","first-page":"997","volume-title":"Brenner and Rector's The Kidney","author":"DB Mount","year":"2004","unstructured":"Mount, D. B. & Zandi-Nejad, K. in Brenner and Rector's The Kidney (ed. Brenner, B. M.) 997\u20131040 (WB Saunders, Philadelphia, 2004)."},{"key":"BFnrneph2012217_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0272-6386(12)80110-7","volume":"18","author":"MM Salem","year":"1991","unstructured":"Salem, M. M., Rosa, R. M. & Batlle, D. C. Extrarenal potassium tolerance in chronic renal failure: implications for the treatment of acute hyperkalemia. Am. J. Kidney Dis. 18, 421\u2013440 (1991).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012217_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0002-9343(88)80086-X","volume":"85","author":"A Blumberg","year":"1988","unstructured":"Blumberg, A., Weidmann, P., Shaw, S. & Gn\u00e4dinger, M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am. J. Med. 85, 507\u2013512 (1988).","journal-title":"Am. J. Med."},{"key":"BFnrneph2012217_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJM198002213020803","volume":"302","author":"RM Rosa","year":"1980","unstructured":"Rosa, R. M.  et al. Adrenergic modulation of extrarenal potassium disposal. N. Engl. J. Med. 302, 431\u2013434 (1980).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012217_CR48","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ki.1978.114","volume":"14","author":"T Berl","year":"1978","unstructured":"Berl, T., Katz, F. H., Henrich, W. L., de Torrente, A. & Schrier, R. W. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 14, 228\u2013235 (1978).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR49","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/ki.1972.23","volume":"1","author":"RW Schrier","year":"1972","unstructured":"Schrier, R. W. & Regal, E. M. Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease. Kidney Int. 1, 156\u2013168 (1972).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrneph.2011.175","volume":"8","author":"DA Sica","year":"2011","unstructured":"Sica, D. A. Diuretic use in renal disease. Nat. Rev. Nephrol. 8, 100\u2013109 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2012217_CR51","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/ki.1983.208","volume":"24","author":"GO Perez","year":"1983","unstructured":"Perez, G. O., Pelleya, R., Oster, J. R., Kem, D. C. & Vaamonde, C. A. Blunted kaliuresis after an acute potassium load in patients with chronic renal failure. Kidney Int. 24, 656\u2013662 (1983).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR52","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/HYPERTENSIONAHA.108.125252","volume":"53","author":"RA Preston","year":"2009","unstructured":"Preston, R. A.  et al. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. Hypertension 53, 754\u2013760 (2009).","journal-title":"Hypertension"},{"key":"BFnrneph2012217_CR53","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11255-004-6193-z","volume":"36","author":"CG Musso","year":"2004","unstructured":"Musso, C. G. Potassium metabolism in patients with chronic kidney disease (CKD), Part I: patients not on dialysis (stages 3\u20134). Int. Urol. Nephrol. 36, 465\u2013468 (2004).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrneph2012217_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","volume":"54","author":"Y Miao","year":"2011","unstructured":"Miao, Y.  et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54, 44\u201350 (2011).","journal-title":"Diabetologia"},{"key":"BFnrneph2012217_CR55","doi-asserted-by":"crossref","unstructured":"Kidney Disease Outcomes Quality Initiative (K\/DOQI). (K\/DOQI) clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 43, S1\u2013290 (2004).","DOI":"10.1053\/j.ajkd.2004.03.003"},{"key":"BFnrneph2012217_CR56","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJM199808133390707","volume":"339","author":"FJ Gennari","year":"1998","unstructured":"Gennari, F. J. Hypokalemia. N. Engl. J. Med. 339, 451\u2013458 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012217_CR57","first-page":"49","volume":"20","author":"CB Raymond","year":"2010","unstructured":"Raymond, C. B., Sood, A. R. & Wazny, L. D. Treatment of hyperkalemia in patients with chronic kidney disease\u2013a focus on medications. CANNT J. 20, 49\u201353; quiz 54\u201355 (2010).","journal-title":"CANNT J."},{"key":"BFnrneph2012217_CR58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B.  et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012217_CR59","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","volume":"118","author":"B Pitt","year":"2008","unstructured":"Pitt, B., Bakris, G., Ruilope, L. M., DiCarlo, L. & Mukherjee, R., EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118, 1643\u20131650 (2008).","journal-title":"Circulation"},{"key":"BFnrneph2012217_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad, F.  et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11\u201321 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012217_CR61","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJM199102143240707","volume":"324","author":"C Take","year":"1991","unstructured":"Take, C., Ikeda, K., Kurasawa, T. & Kurokawa, K. Increased chloride reabsorption as an inherited renal tubular defect in familial type II pseudohypoaldosteronism. N. Engl. J. Med. 324, 472\u2013476 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012217_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/ajkd.1998.v32.pm9669423","volume":"32","author":"M Chacko","year":"1998","unstructured":"Chacko, M., Fordtran, J. S. & Emmett, M. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]\/[Na] ratio, and fractional excretion of potassium. Am. J. Kidney Dis. 32, 47\u201351 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012217_CR63","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1681\/ASN.2007091017","volume":"19","author":"MJ Choi","year":"2008","unstructured":"Choi, M. J. & Ziyadeh, F. N. The utility of the transtubular potassium gradient in the evaluation of hyperkalemia. J. Am. Soc. Nephrol. 19, 424\u2013426 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012217_CR64","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJM198511073131902","volume":"313","author":"D Armanini","year":"1985","unstructured":"Armanini, D.  et al. Aldosterone-receptor deficiency in pseudohypoaldosteronism. N. Engl. J. Med. 313, 1178\u20131181 (1985).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012217_CR65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0889-8529(18)30101-4","volume":"23","author":"CE Kater","year":"1994","unstructured":"Kater, C. E. & Biglieri, E. G. Disorders of steroid 17 \u03b1-hydroxylase deficiency. Endocrinol. Metab. Clin. North Am. 23, 341\u2013357 (1994).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"BFnrneph2012217_CR66","first-page":"399","volume":"75","author":"BA Clark","year":"1992","unstructured":"Clark, B. A., Brown, R. S. & Epstein, F. H. Effect of atrial natriuretic peptide on potassium-stimulated aldosterone secretion: potential relevance to hypoaldosteronism in man. J. Clin. Endocrinol. Metab. 75, 399\u2013403 (1992).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2012217_CR67","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/1479-5876-9-180","volume":"9","author":"RJ Eudy","year":"2011","unstructured":"Eudy, R. J.  et al. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. J. Transl. Med. 9, 180 (2011).","journal-title":"J. Transl. Med."},{"key":"BFnrneph2012217_CR68","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cpt1975184391","volume":"18","author":"L Ramsay","year":"1975","unstructured":"Ramsay, L., Harrison, I., Shelton, J. & Tidd, M. Relative potency of prorenoate and spironolactone in normal man. Clin. Pharmacol. Ther. 18, 391\u2013400 (1975).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrneph2012217_CR69","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2125.1976.tb00624.x","volume":"3","author":"LE Ramsay","year":"1976","unstructured":"Ramsay, L. E., Shelton, J. R. & Tidd, M. J. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects. Br. J. Clin. Pharmacol. 3, 475\u2013482 (1976).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrneph2012217_CR70","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(60)90447-5","volume":"1","author":"CJ Edmonds","year":"1960","unstructured":"Edmonds, C. J. & Wilson, G. M. The action of hydroflumethiazide in relation to adrenal steroids and potassium loss. Lancet 1, 505\u2013509 (1960).","journal-title":"Lancet"},{"key":"BFnrneph2012217_CR71","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/bmj.4.5732.401","volume":"4","author":"RC Eggert","year":"1970","unstructured":"Eggert, R. C. Spironolactone diuresis in patients with cirrhosis and ascites. Br. Med. J. 4, 401\u2013403 (1970).","journal-title":"Br. Med. J."},{"key":"BFnrneph2012217_CR72","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000168062","volume":"10","author":"KS Kamel","year":"1990","unstructured":"Kamel, K. S., Ethier, J. H., Richardson, R. M., Bear, R. A. & Halperin, M. L. Urine electrolytes and osmolality: when and how to use them. Am. J. Nephrol. 10, 89\u2013102 (1990).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2012217_CR73","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/BF00606552","volume":"09","author":"D Levine","year":"1976","unstructured":"Levine, D., Ramsay, L., Auty, R., Branch, R. & Tidd, M. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone. Eur. J. Clin. Pharmacol. 09, 381\u2013386 (1976).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BFnrneph2012217_CR74","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2125.1982.tb01413.x","volume":"13","author":"GT McInnes","year":"1982","unstructured":"McInnes, G. T., Perkins, R. M., Shelton, J. R. & Harrison, I. R. Spironolactone dose-response relationships in healthy subjects. Br. J. Clin. Pharmacol. 13, 513\u2013518 (1982).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrneph2012217_CR75","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0272-6386(12)80076-X","volume":"15","author":"JH Ethier","year":"1990","unstructured":"Ethier, J. H., Kamel, K. S., Magner, P. O., Lemann, J. Jr & Halperin, M. L. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am. J. Kidney Dis. 15, 309\u2013315 (1990).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012217_CR76","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF00858819","volume":"4","author":"J Rodr\u00edguez-Soriano","year":"1990","unstructured":"Rodr\u00edguez-Soriano, J., Ubetagoyena, M. & Vallo, A. Transtubular potassium concentration gradient: a useful test to estimate renal aldosterone bio-activity in infants and children. Pediatr. Nephrol. 4, 105\u2013110 (1990).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2012217_CR77","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000046044","volume":"89","author":"H Mayan","year":"2001","unstructured":"Mayan, H., Kantor, R. & Farfel, Z. Trans-tubular potassium gradient in patients with drug-induced hyperkalemia. Nephron 89, 56\u201361 (2001).","journal-title":"Nephron"},{"key":"BFnrneph2012217_CR78","first-page":"551","volume":"18","author":"C Musso","year":"2007","unstructured":"Musso, C.  et al. Correlation between creatinine clearance and transtubular potassium concentration gradient in old people and chronic renal disease patients. Saudi J. Kidney Dis. Transpl. 18, 551\u2013555 (2007).","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"BFnrneph2012217_CR79","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000167502","volume":"7","author":"RM Zettle","year":"1987","unstructured":"Zettle, R. M.  et al. Renal potassium handling during states of low aldosterone bio-activity: a method to differentiate renal and non-renal causes. Am. J. Nephrol. 7, 360\u2013366 (1987).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2012217_CR80","first-page":"1","volume":"51","author":"H Fujii","year":"2005","unstructured":"Fujii, H.  et al. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. Kobe J. Med. Sci. 51, 1\u20136 (2005).","journal-title":"Kobe J. Med. Sci."},{"key":"BFnrneph2012217_CR81","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1034\/j.1600-0676.2001.01693.x","volume":"22","author":"YS Lim","year":"2002","unstructured":"Lim, Y. S.  et al. Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites. Liver 22, 426\u2013432 (2002).","journal-title":"Liver"},{"key":"BFnrneph2012217_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1523-1755.2002.00350.x","volume":"62","author":"FJ Gennari","year":"2002","unstructured":"Gennari, F. J. & Segal, A. S. Hyperkalemia: an adaptive response in chronic renal insufficiency. Kidney Int. 62, 1\u20139 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR83","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s11606-009-1228-x","volume":"25","author":"MA Raebel","year":"2010","unstructured":"Raebel, M. A.  et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J. Gen. Intern. Med. 25, 326\u2013333 (2010).","journal-title":"J. Gen. Intern. Med."},{"key":"BFnrneph2012217_CR84","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2215\/CJN.07821109","volume":"5","author":"MR Weir","year":"2010","unstructured":"Weir, M. R. & Rolfe, M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin. J. Am. Soc. Nephrol. 5, 531\u2013548 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2012217_CR85","unstructured":"Lambers Heerspink, H. J., Laverman, G. D., Lewis, J., Parving, H.-H. & de Zeeuw, D. Both hypokalemia and hyperkalemia predict cardiovascular risk during blood pressure lowering therapy in patients with diabetes and nephropathy [abstract # SA-PO2407, 663A]. J. Am. Soc. Nephrol. 21, (2010)."},{"key":"BFnrneph2012217_CR86","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink, D. N.  et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543\u2013551 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012217_CR87","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1093\/ndt\/gfg388","volume":"18","author":"P Saudan","year":"2003","unstructured":"Saudan, P.  et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol. Dial. Transplant. 18, 2359\u20132363 (2003).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012217_CR88","doi-asserted-by":"crossref","unstructured":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol. 78, 902\u2013907 (1996).","DOI":"10.1016\/S0002-9149(96)00465-1"},{"key":"BFnrneph2012217_CR89","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"KJ Schjoedt","year":"2004","unstructured":"Schjoedt, K. J., Andersen, S., Rossing, P., Tarnow, L. & Parving, H. H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47, 1936\u20131939 (2004).","journal-title":"Diabetologia"},{"key":"BFnrneph2012217_CR90","doi-asserted-by":"publisher","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","volume":"285","author":"J Fagart","year":"2010","unstructured":"Fagart, J.  et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J. Biol. Chem. 285, 29932\u201329940 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2012217_CR91","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1254\/jphs.10285FP","volume":"115","author":"T Nariai","year":"2011","unstructured":"Nariai, T.  et al. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity. J. Pharmacol. Sci. 115, 346\u2013353 (2011).","journal-title":"J. Pharmacol. Sci."},{"key":"BFnrneph2012217_CR92","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000335559","volume":"89","author":"T Nariai","year":"2012","unstructured":"Nariai, T.  et al. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone\/salt-treated rats. Pharmacology 89, 44\u201352 (2012).","journal-title":"Pharmacology"},{"key":"BFnrneph2012217_CR93","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/FJC.0b013e3182495543","volume":"59","author":"T Nariai","year":"2012","unstructured":"Nariai, T.  et al. SM-368229, a novel promising mineralocorticoid receptor antagonist, shows anti-hypertensive efficacy with minimal effect on serum potassium level in rats. J. Cardiovasc. Pharmacol. 59, 458\u2013464 (2012).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFnrneph2012217_CR94","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/ki.2009.9","volume":"75","author":"WB Lea","year":"2009","unstructured":"Lea, W. B.  et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 75, 936\u2013944 (2009).","journal-title":"Kidney Int."},{"key":"BFnrneph2012217_CR95","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1124\/jpet.110.167148","volume":"334","author":"DF Rigel","year":"2010","unstructured":"Rigel, D. F.  et al. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone. J. Pharmacol. Exp. Ther. 334, 232\u2013243 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrneph2012217_CR96","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar, L.  et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56, 831\u2013838 (2010).","journal-title":"Hypertension"},{"key":"BFnrneph2012217_CR97","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","volume":"124","author":"DA Calhoun","year":"2011","unstructured":"Calhoun, D. A.  et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 124, 1945\u20131955 (2011).","journal-title":"Circulation"},{"key":"BFnrneph2012217_CR98","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/emj.19.1.92-a","volume":"19","author":"M Davey","year":"2002","unstructured":"Davey, M. & Caldicott, D. Calcium salts in management of hyperkalaemia. Emerg. Med. J. 19, 92\u201393 (2002).","journal-title":"Emerg. Med. J."},{"key":"BFnrneph2012217_CR99","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000167176","volume":"6","author":"RA Sherman","year":"1986","unstructured":"Sherman, R. A., Hwang, E. R., Bernholc, A. S. & Eisinger, R. P. Variability in potassium removal by hemodialysis. Am. J. Nephrol. 6, 284\u2013288 (1986).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2012217_CR100","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1136\/pgmj.77.914.759","volume":"77","author":"A Rastegar","year":"2001","unstructured":"Rastegar, A. & Soleimani, M. Hypokalaemia and hyperkalaemia. Postgrad. Med. J. 77, 759\u2013764 (2001).","journal-title":"Postgrad. Med. J."},{"key":"BFnrneph2012217_CR101","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1681\/ASN.2010010079","volume":"21","author":"RH Sterns","year":"2010","unstructured":"Sterns, R. H., Rojas, M., Bernstein, P. & Chennupati, S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J. Am. Soc. Nephrol. 21, 733\u2013735 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012217_CR102","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt, B.  et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur. Heart J. 32, 820\u2013828 (2011).","journal-title":"Eur. Heart J."},{"key":"BFnrneph2012217_CR103","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt, B.  et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309\u20131321 (2003).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.217","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:38:52Z","timestamp":1684471132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,16]]},"references-count":103,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["BFnrneph2012217"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2012.217","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,16]]}}}